Acurx Pharmaceuticals, Inc. announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company s recently completed Phase 2b clinical.
Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin.
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing inn.
Clinical Data Abstract Presentation; IP Portfolio of 9 Patents; Phase 3 Cancer Treatments: RenovoRx NASDAQ: RNXT $RNXT einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.